Clinical Impact of the FilmArray Blood Culture Identification Panel Performed on Positive Blood Cultures From Intensive Care Patients With Septicemia
Overview
Molecular testing is a largely validated approach allowing rapid identification of positive blood cultures. However, due to its high cost and its limited information on susceptibility, it is considered as an add-on technique reserved for specific patient populations. In our study, we specifically evaluated molecular testing in a critical care setting and measured its impact on the therapeutic management of critically ill with positive blood cultures. Through the analysis of 110 positive blood culture episodes included in both pre- and post intervention period, we measured a drastic 14h-reduction of the time to administration of the optimal antimicrobial treatment with the use of the molecular approach.
Full Title of Study: “The Impact of a Rapid Molecular Identification Test on Positive Blood Cultures From Critically Ill With Bacteremia: a Pre-post Intervention Study”
Study Type
- Study Type: Observational [Patient Registry]
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 31, 2017
Interventions
- Diagnostic Test: FilmArray blood culture identification panel
- FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
Clinical Trial Outcome Measures
Primary Measures
- Turn Around Time to optimal treatment of septicemia
- Time Frame: From positivity detection of positive blood culture to administration of optimal treatment (up to 48 hours)
- Time in minutes
Participating in This Clinical Trial
Inclusion Criteria
- adult intensive care unit patients with positive blood cultures Exclusion Criteria:
- palliative care patients
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Investigator Details
- Lead Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Collaborator
- BioMérieux
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Alexia VERROKEN, Principal Investigator, Cliniques universitaires St-Luc
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.